Rezolute, Inc. (RZLT)
Rezolute, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Redwood City, CA, US. The stock last traded at $3.92, down 6.67% on the session, giving a market capitalisation of $379.2M. On trailing twelve-month figures it carries a trailing P/E of -5.16, a net margin of 0.0%. Its beta of 0.62 implies it has historically moved less than the broad market.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc. is most often compared with the following Healthcare names: